Analysis of adrenaline autoinjectors acquisition in Portugal over 15 years
M. Fernandes firstname.lastname@example.org,2
, T. Lourenço1
, A. Spínola Santos1
, M. Pereira Barbosa1,3Show more: Authors information and Publication history
Serviço de Imunoalergologia, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa Norte EPE, Lisbon, Portugal2
Unidade de Imunoalergologia, Hospital Dr. Nélio Mendonça, SESARAM EPE, Funchal, Portugal3
Clínica Universitária de Imunoalergologia, Faculdade de Medicina da Universidade de Lisboa, Lison, Portugal
Published: 04 May 2021
Accepted: 12 April 2021
Received: 15 December 2021
The adrenaline autoinjector (AAi) is universally recommended as the first-line treatment for anaphylactic reactions occurring outside the medical setting. The quantification of its acquisition may help estimate the prevalence of patients at risk of anaphylaxis with an indication for AAi. Objective.
Evaluation of the global and regional frequency of AAi purchases in Mainland Portugal between 2003-2017 and calculate the inherent costs in 2017. Methods.
AAi acquisition distribution analysis along this period. The population was divided in two age groups according to the adrenaline dosage. Results.
A total of 10,993 AAi units of 0.15mg/0.3mL and 28,619 of 0.3mg/0.3mL were acquired in these 15 years, with an annual average of 733 and 1908 units, respectively. In cumulative values terms, Lisbon showed the highest number of AAI acquired and higher prevalence per region/100,000 inhabitants in both groups. In 2017, the annual cost for each age group was 64,202.71 € 187,447.70 € for patients and € 37,706.35 /110,113.30 € for the National Health System. Conclusions.
In the last 15 years, there was a progressive increase in AAi acquisition. We estimate a rate of anaphylaxis occurrence in Portugal according to AAi aquisition of 0.165%.
Adrenaline auto-injector; anaphylaxis; acquisition; prescription; prevalence. FULL TEXT